Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.33
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.33
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.28 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)53.21K
Market Cap
AU$63.73M
Enterprise ValueAU$102.25M
Total Cash (Recent Filing)AU$17.18M
Total Debt (Recent Filing)AU$5.46M
Price to Earnings (P/E)―
Beta1.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume44,892
30 Day Avg. Volume53,212
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)2.37
Price to Sales (P/S)0.98
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.76Price Target Upside130.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving EBITDA And Cash GenerationImproving EBITDA and operating cash flow indicate stronger operating discipline and better conversion of the appliance business into financial resources. Sustained margin improvement can support reinvestment in capacity, product development and commercial execution while strengthening resilience over the next several quarters.
Conservative Balance SheetLow leverage gives SomnoMed greater financial flexibility than in 2023, when debt was high relative to equity. A stronger capital base can reduce balance-sheet strain, support continued investment in growth initiatives and improve the company’s ability to manage operational volatility.
Manufacturing Scale And Product InnovationExpanded capacity and faster production turnaround should improve service capability as demand develops across international markets. Virtus also targets OSA patients with bruxism, an underserved segment, giving SomnoMed a potential product-led avenue to broaden adoption of oral appliance therapy.
Bears Say
Structural European Reimbursement HeadwindsEurope is SomnoMed’s largest region, so changes to eligibility, reimbursement and referral pathways can affect both patient access and clinician adoption. These structural pressures may weigh on regional growth for multiple quarters and require restructuring to restore commercial momentum.
Net Losses And Weak Shareholder ReturnsAlthough operating profitability has improved, persistent net losses show that costs below EBIT still prevent the business from producing positive earnings for shareholders. Negative returns on equity could constrain internally funded growth and make sustained profitability a key execution requirement.
Intensifying Competitive AlternativesA wider set of treatment options and lower-cost alternatives can make clinical differentiation and patient acquisition more difficult. If adoption pathways shift toward competing therapies or direct-to-consumer models, SomnoMed may face longer-term pressure on market share and pricing power.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.28 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$63.73M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q4 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$0.76
▲(130.30% Upside)